Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
Healthcare firms are already known for being volatile, with smaller companies in particular experiencing significant spikes and dips alongside news of successes or failures in the clinical drug development space. Three companies stand out as we reach the midpoint of 2025 for their massive growth potential.
